Latest / Stock Picking with Fexingo: Individual Equities, Research, and Building a Concentrated Portfolio
How Pfizer and Bristol Myers Are Winning the Biopharma Turnaround
With big pharma stocks languishing for years, two names have quietly broken out in 2026: Pfizer and Bristol Myers Squibb. Lucas walks through the specific pipeline catalysts, margin recovery levers, and management moves that separate these two from their peers. He explains how Pfizer's oncology pivot and Bristol Myers' cost restructuring are showing up in free cash flow and gross margin data. Luna pushes back on patent cliff risks and asks whether this is a genuine turnaround or just a relief rally. They discuss the role of M&A discipline, the right valuation entry points, and what…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.